Cargando…
The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study
BACKGROUND: Research into the potential utility of plasma-derived circulating cell-free nucleic acids as non-invasive adjuncts to radiological imaging have been occasioned by the invasive nature of brain tumour biopsy. The objective of this study was to determine whether significant differences exis...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913523/ https://www.ncbi.nlm.nih.gov/pubmed/34643804 http://dx.doi.org/10.1007/s00701-021-05014-8 |
_version_ | 1784667460305158144 |
---|---|
author | Ita, Michael Itak Wang, Jiang Huai Toulouse, André Lim, Chris Fanning, Noel O’Sullivan, Michael Nolan, Yvonne Kaar, George Finbarr Redmond, Henry Paul |
author_facet | Ita, Michael Itak Wang, Jiang Huai Toulouse, André Lim, Chris Fanning, Noel O’Sullivan, Michael Nolan, Yvonne Kaar, George Finbarr Redmond, Henry Paul |
author_sort | Ita, Michael Itak |
collection | PubMed |
description | BACKGROUND: Research into the potential utility of plasma-derived circulating cell-free nucleic acids as non-invasive adjuncts to radiological imaging have been occasioned by the invasive nature of brain tumour biopsy. The objective of this study was to determine whether significant differences exist in the plasma transcriptomic profile of glioma patients relative to differences in their tumour characteristics, and also whether any observed differences were representative of synchronously obtained glioma samples and TCGA glioma-derived RNA. METHODS: Blood samples were collected from twenty glioma patients prior to tumour resection. Plasma ccfmRNAs and glioma-derived RNA were extracted and profiled. RESULTS: BCL2L1, GZMB, HLA-A, IRF1, MYD88, TLR2, and TP53 genes were significantly over-expressed in glioma patients (p < 0.001, versus control). GZMB and HLA-A genes were significantly over-expressed in high-grade glioma patients (p < 0.001, versus low-grade glioma patients). Moreover, the fold change of the BCL2L1 gene was observed to be higher in patients with high-grade glioma (p = 0.022, versus low-grade glioma patients). There was positive correlation between the magnitude of fold change of differentially expressed genes in plasma- and glioma-derived RNA (Spearman r = 0.6344, n = 14, p = 0.017), and with the mean FPKM in TCGA glioma-derived RNA samples (Spearman r = 0.4614, n = 19, p < 0.05). There was positive correlation between glioma radiographic tumour burden and the magnitude of fold change of the CSF3 gene (r = 0.9813, n = 20, p < 0.001). CONCLUSION: We identified significant differential expression of genes involved in cancer inflammation and immunity crosstalk among patients with different glioma grades, and there was positive correlation between their transcriptomic profile in plasma and tumour samples, and with TCGA glioma-derived RNA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00701-021-05014-8. |
format | Online Article Text |
id | pubmed-8913523 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Vienna |
record_format | MEDLINE/PubMed |
spelling | pubmed-89135232022-03-15 The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study Ita, Michael Itak Wang, Jiang Huai Toulouse, André Lim, Chris Fanning, Noel O’Sullivan, Michael Nolan, Yvonne Kaar, George Finbarr Redmond, Henry Paul Acta Neurochir (Wien) Original Article - Brain Tumors BACKGROUND: Research into the potential utility of plasma-derived circulating cell-free nucleic acids as non-invasive adjuncts to radiological imaging have been occasioned by the invasive nature of brain tumour biopsy. The objective of this study was to determine whether significant differences exist in the plasma transcriptomic profile of glioma patients relative to differences in their tumour characteristics, and also whether any observed differences were representative of synchronously obtained glioma samples and TCGA glioma-derived RNA. METHODS: Blood samples were collected from twenty glioma patients prior to tumour resection. Plasma ccfmRNAs and glioma-derived RNA were extracted and profiled. RESULTS: BCL2L1, GZMB, HLA-A, IRF1, MYD88, TLR2, and TP53 genes were significantly over-expressed in glioma patients (p < 0.001, versus control). GZMB and HLA-A genes were significantly over-expressed in high-grade glioma patients (p < 0.001, versus low-grade glioma patients). Moreover, the fold change of the BCL2L1 gene was observed to be higher in patients with high-grade glioma (p = 0.022, versus low-grade glioma patients). There was positive correlation between the magnitude of fold change of differentially expressed genes in plasma- and glioma-derived RNA (Spearman r = 0.6344, n = 14, p = 0.017), and with the mean FPKM in TCGA glioma-derived RNA samples (Spearman r = 0.4614, n = 19, p < 0.05). There was positive correlation between glioma radiographic tumour burden and the magnitude of fold change of the CSF3 gene (r = 0.9813, n = 20, p < 0.001). CONCLUSION: We identified significant differential expression of genes involved in cancer inflammation and immunity crosstalk among patients with different glioma grades, and there was positive correlation between their transcriptomic profile in plasma and tumour samples, and with TCGA glioma-derived RNA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00701-021-05014-8. Springer Vienna 2021-10-13 2022 /pmc/articles/PMC8913523/ /pubmed/34643804 http://dx.doi.org/10.1007/s00701-021-05014-8 Text en © The Author(s) 2021, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article - Brain Tumors Ita, Michael Itak Wang, Jiang Huai Toulouse, André Lim, Chris Fanning, Noel O’Sullivan, Michael Nolan, Yvonne Kaar, George Finbarr Redmond, Henry Paul The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study |
title | The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study |
title_full | The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study |
title_fullStr | The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study |
title_full_unstemmed | The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study |
title_short | The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study |
title_sort | utility of plasma circulating cell-free messenger rna as a biomarker of glioma: a pilot study |
topic | Original Article - Brain Tumors |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913523/ https://www.ncbi.nlm.nih.gov/pubmed/34643804 http://dx.doi.org/10.1007/s00701-021-05014-8 |
work_keys_str_mv | AT itamichaelitak theutilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy AT wangjianghuai theutilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy AT toulouseandre theutilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy AT limchris theutilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy AT fanningnoel theutilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy AT osullivanmichael theutilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy AT nolanyvonne theutilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy AT kaargeorgefinbarr theutilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy AT redmondhenrypaul theutilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy AT itamichaelitak utilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy AT wangjianghuai utilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy AT toulouseandre utilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy AT limchris utilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy AT fanningnoel utilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy AT osullivanmichael utilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy AT nolanyvonne utilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy AT kaargeorgefinbarr utilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy AT redmondhenrypaul utilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy |